|[February 04, 2014]
Agenus Announces Public Offering of Common Stock
LEXINGTON, Mass. --(Business Wire)--
Agenus Inc. (Nasdaq: AGEN) today announced that it has commenced an
underwritten public offering of shares of its common stock. All of the
shares in the offering are to be sold by Agenus.
William Blair & Company, L.L.C. is acting as sole book-running manager
for the offering. Agenus intends to grant the underwriters a 30-day
option to purchase up to an additional 15 percent of the amount sold to
cover over-allotments, if any. The offering is subject to market
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
The shares will be issued by Agenus pursuant to a shelf registration
statement that was previously filed with, and declared effective by, the
Securities and Exchange Commission (SEC (News - Alert)). A preliminary prospectus
supplement related to the offering has been filed with the SEC and is
available on the SEC's website located at www.sec.gov.
A final prospectus supplement related to the offering will be filed with
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at all, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of the
effective registration statement, copies of which may be obtained, when
available, from William Blair & Company, L.L.C., Attention: Prospectus
Department, 222 West Adams Street, Chicago, IL 60606, by telephone at
(800) 621-0687, or by e-mail at firstname.lastname@example.org.
Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on
immunotherapeutic products based on strong platform technologies with
multiple product candidates advancing through the clinic, including
several product candidates that have advanced into late-stage clinical
trials through corporate partners. Between Agenus and its partners, 23
programs are in clinical development.
Statements made in this press release include forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, regarding, but not limited to, the use of proceeds from the
offering. Forward-looking statements can be identified by the use of
words such as "may," "will," "plan," "should," "expect," "anticipate,"
"estimate," "continue," or comparable terminology. Such forward-looking
statements are inherently subject to certain risks, trends and
uncertainties, many of which Agenus cannot predict with accuracy and
some of which Agenus might not even anticipate, and involve factors that
may cause actual results to differ materially from those projected or
suggested. These risks and uncertainties include, among others, the
factors described under the Risk Factors section of Agenus' Current
Report on Form 8-K, which was filed with the SEC on February 4, 2014.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These statements
speak only as of the date of this press release, and Agenus undertakes
no obligation to update or revise the statements.
[ Back To TMCnet.com's Homepage ]